吉非替尼对晚期肺腺癌患者疗效及与皮疹的相关性

摘要

目的：分析晚期肺腺癌患者使用吉非替尼后其疗效及与皮疹之间的相关性。方法：对我院自2009年1月至2012年1月收治的56例晚期肺腺癌患者使用吉非替尼后出现的不良反应进行分析，比较皮疹与疗效之间关系。结果：使用吉非替尼后，皮疹、肝功能异常、胃肠道反应及急性间质性肺炎的发生率分别为44.6%、32.1%、17.9%及7.1%。与未出现皮疹患者相比较，使用吉非替尼出现皮疹的患者，其客观有效率明显升高（ P﹤0.01）。结论：使用吉非替尼后出现皮疹的患者其客观有效率较未出现皮疹患者高。%Objective:We analyzed clinical course of lung adenocarcinoma and assessed the relation between sKin rash and efficacy of gefitinib. Methods:Between January 2009 and January 2012,We analyzed adverse events of 56 lung cancer patients administered gefitinib and assessed the relation between sKin rash and efficacy of gefitinib. Re-sults:In all 56 cases,sKin trouble developed in 44. 6%,liver damage occurred in 32. 1%,diarrhea in 17. 9% and a-cute lung injury in 7. 1%. The ORR of sKin rash was superior to those without sKin rash(P﹤0. 01). Conclusion:The objective response among the patients with sKin rash was significantly superior to the patients without sKin rash.